• Product NameJI-101
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityJI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4). JI-101 inhibits angiogenesis, and subsequently tumor growth.
• Target NameEphrin Receptor inhibitor; PDGFR inhibitor; VEGFR inhibitor
• CAS No. 900573-88-8
• Calculated MW 466.339
• Formulation C22H20BrN5O2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular
  SMILES:COC1=C(C=C(C=C1)Br)NC(=O)NC2=CC=CC3=C2C=CN3CC4=CC(=NC=C4)N
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:Ephrin Receptor; PDGFR; VEGFR
  Boling pt:
  Melting pt:
  Solubility:DMSO: 10 mM
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1.Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs, December 2015, Volume 33, Issue 6, pp 1217-1224

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting